Search
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
Read moreTreatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab
The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.
Read moreHighlights from the SWG
EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.
SWG Educational Activities
MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget
Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).
Selected EMA news
December 2024New information on approved medicines
Sarclisa (isatuximab) - new indication
Treatment of multiple myeloma (a type of blood cancer)
Withdrawal of applications for extension of indication
Inaqovi (cedazuridine / decitabine)
Treatment of different types of blood cancer
Direct Healthcare Professional Communication (DHPC)
Pegasys (peginterferon alfa-2a)
Treatment of…
Highlights of Past EHA - Cairo 2017
Dates: September 14 - 15, 2017
Location: Cairo, Egypt
Chairs:
Prof Azza Kamel, Secretary General, Egyptian Society of Hematology and Research (ESHR)
Prof Amal El-Beshlawy, Vice President, Egyptian Society of Hematology and Research (ESHR)
Prof John Gribben, President elect, European Hematology Association (EHA)
Prof Mohamad Qari, President, Pan…
EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies
In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)
Online registration is closed.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- »